Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

13 evidence topics · 11 sources

Donidalorsen: mean attack rate per four weeks in OASIS-HAE